Founded in 2010, Avraham said it had now raised $14.7m to test patients with Alzheimer's disease after a $9m round in April 2010.
Avraham Pharmaceuticals, an Israel-based drugs developer, has raised $5.7m from a consortium including Tel Aviv-listed Clal Biotechnology and university venturing funds. Founded in 2010, Avraham said it had now raised $14.7m to to test patients with Alzheimer’s disease after a $9m round in April 2010. The other investors in the round were Yissum Technology Transfer…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
